Learn more

NAPO PHARMACEUTICALS INC

Overview
  • Total Patents
    81
  • GoodIP Patent Rank
    78,943
About

NAPO PHARMACEUTICALS INC has a total of 81 patent applications. Its first patent ever was published in 1997. It filed its patents most often in EPO (European Patent Office), Australia and United States. Its main competitors in its focus markets pharmaceuticals, basic materials chemistry and organic fine chemistry are ARJUNA NATURAL EXTRACTS LTD, LEOPOLDO DE JESUS ESPINOSA ABD and SD PHARMACEUTICALS INC.

Patent filings per year

Chart showing NAPO PHARMACEUTICALS INCs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Quart Barry 36
#2 Rosenbaum David 29
#3 Neenan Thomas 14
#4 Chaturvedi Pravin R 13
#5 Blanks Robert 12
#6 Conte Lisa A 10
#7 Chaturvedi Pravin 10
#8 Bortey Enoch 7
#9 Conte Charles 6
#10 Forbes William 6

Latest patents

Publication Filing date Title
AU2018278312A1 Methods and compositions for treating congenital diarrhea disorder
AU2018275685A1 Methods and compositions for treating bile acid diarrhea, diarrhea associated with small intestine resection or gallbladder removal, and short bowel syndrome
US2020345687A1 Methods and compositions for treating chemotherapy-induced diarrhea
AU2013203794A1 Method for treatment of constipation-predominant irritable bowel syndrome
AU2013205344A1 Method for treatment of diarrhea-predominant irritable bowel syndrome
AU2013201685A1 Compositions and methods for treating or preventing inflammatory bowel disease, familial adenomatous polyposis and colon cancer
EP2699236A1 Pharmacologically optimized multimodal drug delivery system for nordihydroguiaretic acid (ndga)
HUE035393T2 Methods and compositions for treating hiv-associated diarrhea
NZ572048A Method for treatment of diarrhea-predominant irritable bowel syndrome
CA2650294A1 Method for treatment of diarrhea-predominant irritable bowel syndrome
EP2241318A1 Method for treatment of constipation-predominant irritable bowel syndrome
WO2007130893A2 Compositions and methods for treating or preventing inflammatory bowel disease, familial adenomatous polyposis and colon cancer